{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:52:39Z","timestamp":1792511559273,"version":"4.5.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2016,4,25]],"date-time":"2016-04-25T00:00:00Z","timestamp":1461542400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1007\/s40262-016-0391-6","type":"journal-article","created":{"date-parts":[[2016,4,25]],"date-time":"2016-04-25T04:32:53Z","timestamp":1461558773000},"page":"1191-1204","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":67,"title":["Clinical Pharmacokinetics and Pharmacodynamics of Bosutinib"],"prefix":"10.1007","volume":"55","author":[{"given":"Richat","family":"Abbas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poe-Hirr","family":"Hsyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,4,25]]},"reference":[{"issue":"4","key":"391_CR1","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1182\/blood-2007-05-092056","volume":"111","author":"H Konig","year":"2008","unstructured":"Konig H, Holyoake T, Bhatia R. Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual SRC\/ABL kinase inhibitor SKI-606. Blood. 2008;111(4):2329\u201338.","journal-title":"Blood"},{"issue":"17","key":"391_CR2","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","volume":"340","author":"C Sawyers","year":"1999","unstructured":"Sawyers C. Chronic myeloid leukemia. N Engl J Med. 1999;340(17):1330\u201340.","journal-title":"N Engl J Med"},{"issue":"10","key":"391_CR3","first-page":"430","volume":"69","author":"N Thielen","year":"2011","unstructured":"Thielen N, Ossenkoppele GJ, Schuurhuis GJ, Janssen J. New insights into the pathogenesis of chronic myeloid leukaemia: towards a path to cure. Neth J Med. 2011;69(10):430\u201340.","journal-title":"Neth J Med"},{"issue":"7","key":"391_CR4","first-page":"114","volume":"107","author":"N Bubnoff Von","year":"2010","unstructured":"Von Bubnoff N, Duyster J. Chronic myelogenous leukemia\u2014treatment and monitoring. Dtsch Arztebl Int. 2010;107(7):114\u201321.","journal-title":"Dtsch Arztebl Int."},{"issue":"5","key":"391_CR5","doi-asserted-by":"crossref","first-page":"581","DOI":"10.2217\/epi.11.73","volume":"3","author":"C Florean","year":"2011","unstructured":"Florean C, Schnekenburger M, Grandjenette C, Dicato M, Diederich M. Epigenomics of leukemia: from mechanisms to therapeutic applications. Epigenomics. 2011;3(5):581\u2013609.","journal-title":"Epigenomics."},{"issue":"12","key":"391_CR6","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.18632\/aging.100420","volume":"3","author":"G Gugliotta","year":"2011","unstructured":"Gugliotta G, Castagnetti F, Palandri F, Baccarani M, Rosti G. Imatinib in chronic myeloid leukemia elderly patients. Aging. 2011;3(12):1125\u20136.","journal-title":"Aging."},{"issue":"7","key":"391_CR7","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1172\/JCI41246","volume":"120","author":"D Perrotti","year":"2010","unstructured":"Perrotti D, Jamieson C, Goldman J, Skorski T. Chronic myeloid leukemia: mechanisms of blastic transformation. J Clin Invest. 2010;120(7):2254\u201364.","journal-title":"J Clin Invest."},{"issue":"1","key":"391_CR8","doi-asserted-by":"crossref","first-page":"e2015014","DOI":"10.4084\/mjhid.2015.014","volume":"7","author":"IC Haznedaroglu","year":"2015","unstructured":"Haznedaroglu IC. Drug therapy in the progressed CML patient with multi-TKI failure. Mediterr J Hematol Infect Dis. 2015;7(1):e2015014.","journal-title":"Mediterr J Hematol Infect Dis."},{"key":"391_CR9","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1126\/science.289.5486.1938","volume":"289","author":"T Schindler","year":"2000","unstructured":"Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science. 2000;289:1938\u201342.","journal-title":"Science"},{"issue":"8","key":"391_CR10","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1200\/JCO.2003.11.143","volume":"21","author":"MW Deininger","year":"2003","unstructured":"Deininger MW, O\u2019Brien SG, Ford JM, Druker BJ. Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol. 2003;21(8):1637\u201347.","journal-title":"J Clin Oncol"},{"issue":"5","key":"391_CR11","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nrc2126","volume":"7","author":"E Weisberg","year":"2007","unstructured":"Weisberg E, Manley PW, Cowan-Jacob SW, Hochhaus A, Griffin JD. Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer. 2007;7(5):345\u201356.","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"391_CR12","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1634\/theoncologist.2007-0170","volume":"13","author":"P Ramirez","year":"2008","unstructured":"Ramirez P, DiPersio JF. Therapy options in imatinib failures. Oncologist. 2008;13(4):424\u201334.","journal-title":"Oncologist."},{"issue":"8","key":"391_CR13","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1038\/leu.2010.101","volume":"24","author":"M Marega","year":"2010","unstructured":"Marega M, Piazza RG, Pirola A, Redaelli S, Mogavero A, Lacobucci I, et al. BCR and BCR-ABL regulation during myeloid differentiation in healthy donors and in chronic phase\/blast crisis CML patients. Leukemia. 2010;24(8):1445\u20139.","journal-title":"Leukemia"},{"issue":"6","key":"391_CR14","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/leu.2008.84","volume":"22","author":"A Hochhaus","year":"2008","unstructured":"Hochhaus A, Baccarani M, Deininger M, Apperley JF, Lipton JH, Goldberg SL, et al. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia. 2008;22(6):1200\u20136.","journal-title":"Leukemia"},{"issue":"24","key":"391_CR15","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","volume":"354","author":"M Talpaz","year":"2006","unstructured":"Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, et al. Dasatinib in imatinib-resistant Philadelphia chromosome\u2013positive leukemias. N Engl J Med. 2006;354(24):2531\u201341.","journal-title":"N Engl J Med"},{"issue":"6","key":"391_CR16","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1182\/blood-2006-09-047266","volume":"109","author":"A Hochhaus","year":"2007","unstructured":"Hochhaus A, Kantarjian HM, Baccarani M, Lipton JH, Apperley JF, Druker BJ, et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood. 2007;109(6):2303\u20139.","journal-title":"Blood"},{"issue":"24","key":"391_CR17","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","volume":"354","author":"H Kantarjian","year":"2006","unstructured":"Kantarjian H, Giles F, Wunderle L, Bhalla K, O\u2019Brien S, Wassmann B, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome\u2013positive ALL. N Engl J Med. 2006;354(24):2542\u201351.","journal-title":"N Engl J Med"},{"issue":"18","key":"391_CR18","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1002\/cncr.24504","volume":"115","author":"H Kantarjian","year":"2009","unstructured":"Kantarjian H, Pasquini R, Levy V, Jootar S, Holowiecki J, Hamerschlak N, et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase\u00a02 study (START-R). Cancer. 2009;115(18):4136\u201347.","journal-title":"Cancer"},{"issue":"2","key":"391_CR19","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","volume":"7","author":"E Weisberg","year":"2005","unstructured":"Weisberg E, Manley P, Breitenstein W, Brigger J, Cowan Jocab SW, Ray A, et al. Characterization of AMN107, a selective inhibitor of native and mutant BCR-ABL. Cancer Cell. 2005;7(2):129\u201341.","journal-title":"Cancer Cell"},{"issue":"3","key":"391_CR20","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1002\/jcp.25118","volume":"231","author":"R Ciarcia","year":"2016","unstructured":"Ciarcia R, Damiano S, Puzo MV, Montagnaro S, Pagnini F, Pacilio C, et al. Comparison of dasatinib, nilotinib and imatinib in the treatment of chronic myeloid leukemia. J Cell Physiol. 2016;231(3):680\u20137.","journal-title":"J Cell Physiol"},{"key":"391_CR21","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1126\/science.1099480","volume":"305","author":"N Shah","year":"2004","unstructured":"Shah N, Tran C, Lee F, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science. 2004;305:399\u2013401.","journal-title":"Science"},{"key":"391_CR22","doi-asserted-by":"crossref","first-page":"5790","DOI":"10.1158\/0008-5472.CAN-05-4187","volume":"66","author":"J Tokarski","year":"2006","unstructured":"Tokarski J, Newitt J, Chang C, Cheng JD, Witterkind M, Kieffer SE, et al. The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res. 2006;66:5790\u20137.","journal-title":"Cancer Res"},{"issue":"7","key":"391_CR23","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1002\/cncr.24155","volume":"115","author":"HJ Khoury","year":"2009","unstructured":"Khoury HJ, Guilhot F, Hughes TP, Kim DW, Cortes JE. Dasatinib treatment for Philadelphia chromosome\u2013positive leukemias: practical considerations. Cancer. 2009;115(7):1381\u201394.","journal-title":"Cancer"},{"key":"391_CR24","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.sjopt.2014.12.004","volume":"29","author":"KS Monge","year":"2015","unstructured":"Monge KS, Galvez-Ruiz A, Alvarez-Carron A, Quijada C, Matteu A. Optic neuropathy secondary to dasatinib in the treatment of a chronic myeloid leukemia case. Saudi J Ophthalmol. 2015;29:227\u201331.","journal-title":"Saudi J Ophthalmol."},{"key":"391_CR25","first-page":"1","volume":"1","author":"L Kostos","year":"2015","unstructured":"Kostos L, Burbury K, Srivastava G, Prince HM. Gastrointestinal bleeding in a chronic myeloid leukaemia patient precipitated by dasatinib-induced platelet dysfunction: case report. Platelets. 2015;1:1\u20133.","journal-title":"Platelets"},{"issue":"28","key":"391_CR26","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1200\/JCO.2011.38.7522","volume":"30","author":"JE Cortes","year":"2012","unstructured":"Cortes JE, Kim DW, Kantarjian HM, Brummendorf TH, Dyagil I, Griskericius L, et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol. 2012;30(28):3486\u201392.","journal-title":"J Clin Oncol"},{"key":"391_CR27","first-page":"375","volume":"63","author":"M Golas","year":"2003","unstructured":"Golas M, Arndt K, Etienne C, Lucas J, Nardin D, Gibbons J, et al. SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of SRC and ABL kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res. 2003;63:375\u201381.","journal-title":"Cancer Res"},{"key":"391_CR28","doi-asserted-by":"crossref","first-page":"11314","DOI":"10.1158\/0008-5472.CAN-06-1199","volume":"66","author":"M Puttini","year":"2006","unstructured":"Puttini M, Coluccia AM, Boschelli F, Cleris L, Marches E, Donella-Deana A, et al. In\u00a0vitro and in\u00a0vivo activity of SKI-606, a novel SRC-ABL inhibitor, against imatinib-resistant BCR-ABL+ neoplastic cells. Cancer Res. 2006;66:11314\u201322.","journal-title":"Cancer Res"},{"key":"391_CR29","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1200\/JCO.2008.19.8853","volume":"27","author":"S Redaelli","year":"2009","unstructured":"Redaelli S, Piazza R, Rostagno R, Magistroni V, Perini P, Marega M, et al. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR\/ABL mutants. J Clin Oncol. 2009;27:469\u201371.","journal-title":"J Clin Oncol"},{"key":"391_CR30","doi-asserted-by":"crossref","first-page":"4567","DOI":"10.1182\/blood-2011-05-355594","volume":"118","author":"JE Cortes","year":"2011","unstructured":"Cortes JE, Kantarjian HM, Brummendorf TH, Kim DW, Turkina AG, Shen ZX, et al. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome\u2013positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood. 2011;118:4567\u201376.","journal-title":"Blood"},{"key":"391_CR31","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1182\/blood-2007-04-086801","volume":"110","author":"C Gambacorti-Passerini","year":"2007","unstructured":"Gambacorti-Passerini C, Kantarjian H, Bruemmendorf T. Bosutinib (SKI-606) demonstrates clinical activity and is well tolerated among patients with AP and BP CML and Ph+ ALL. Blood. 2007;110:473.","journal-title":"Blood"},{"issue":"15 Suppl.","key":"391_CR32","first-page":"372s","volume":"26","author":"TH Bruemmendorf","year":"2008","unstructured":"Bruemmendorf TH, Cervantes F, Kim D, Chandy TM, Fischer T, Hochhaus A, et al. Bosutinib is safe and active in patients (pts) with chronic phase (CP) chronic myeloid leukemia (CML) with resistance or intolerance to imatinib and other tyrosine kinase inhibitors [abstract no.\u00a07001]. J Clin Oncol. 2008;26(15 Suppl.):372s.","journal-title":"J Clin Oncol"},{"key":"391_CR33","doi-asserted-by":"crossref","first-page":"5523","DOI":"10.1182\/blood.V124.21.5523.5523","volume":"124","author":"V Garc\u00eda-Gutierrez","year":"2014","unstructured":"Garc\u00eda-Gutierrez V, Maestro B, Martinez-Trillo A, Lopez Lorenzo JL, Martin Marteos ML, Alvarez A, et al. Bosutinib appears to be safe, with low cross intolerance, in patients treated in 4th line: results of the Spanish Compassionate Use Program. Blood. 2014;124:5523.","journal-title":"Blood"},{"issue":"5","key":"391_CR34","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/ajh.23973","volume":"90","author":"V Garc\u00eda-Gutierrez","year":"2015","unstructured":"Garc\u00eda-Gutierrez V, Maestro B, Martinez-Trillo A, Bautista G, Martin Mateos ML, Alvarez Larran A, et al. Bosutinib shows low cross intolerance, in chronic myeloid leukemia patients treated in fourth line: results of the Spanish Compassionate Use Program. Am J Hematol. 2015;90(5):429\u201333.","journal-title":"Am J Hematol"},{"key":"391_CR35","unstructured":"Pfizer Ltd. Summary of product characteristics: Bosulif 100\u00a0mg film-coated tablets. London: European Medicines Agency; 2014. http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/002373\/human_med_001613.jsp&mid=WC0b01ac058001d124 . Accessed 19 Mar 2016."},{"key":"391_CR36","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00280-011-1688-7","volume":"69","author":"R Abbas","year":"2012","unstructured":"Abbas R, Hug BA, Leister C, Gaaloul ME, Chalon S, Sonnichsen D. A\u00a0phase\u00a01 ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606)\u00a0in healthy adult subjects. Cancer Chemother Pharmacol. 2012;69:221\u20137.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"12","key":"391_CR37","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1177\/0091270010387427","volume":"51","author":"R Abbas","year":"2011","unstructured":"Abbas R, Hug B, Leister C, Burns J, Sonnichsen D. Effect of ketoconazole on the pharmacokinetics (PK) of bosutinib (SKI-606) in healthy subjects. J Clin Pharmacol. 2011;51(12):1721\u20137.","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"391_CR38","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1515\/dmdi-2014-0026","volume":"30","author":"R Abbas","year":"2015","unstructured":"Abbas R, Boni J, Sonnichsen D. Effect of rifampin on the pharmacokinetics of bosutinib, a dual SRC\/ABL tyrosine kinase inhibitor, when administered concomitantly to healthy subjects. Drug Metabol Personal Ther. 2015;30(1):57\u201363.","journal-title":"Drug Metabol Personal Ther."},{"issue":"6","key":"391_CR39","first-page":"1","volume":"29","author":"PH Hsyu","year":"2014","unstructured":"Hsyu PH, Mould DR, Abbas R, Amantea M. Population pharmacokinetic and pharmacodynamic analysis of bosutinib. Drug Metab Pharmacokinet. 2014;29(6):1\u20138.","journal-title":"Drug Metab Pharmacokinet"},{"key":"391_CR40","unstructured":"US Food and Drug Administration Center for Drug Evaluation and Research [CDER]. Waiver of in\u00a0vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system: guidance for industry. Rockville: CDER; 2000. http:\/\/www.fda.gov\/AboutFDA\/CentersOffices\/OfficeofMedicalProductsandTobacco\/CDER\/ucm128219 . Accessed 11 May 2011."},{"key":"391_CR41","unstructured":"Hsyu PH, Matschke K, Soriano-Pignataro D. Absolute bioavailability of bosutinib in healthy subjects from an open-label, randomized, 2-period crossover study [abstract]. In: 2016 Annual Meeting, American Society for Clinical Pharmacology and Therapeutics; San\u00a0Diego; 8\u201312 Mar 2016."},{"key":"391_CR42","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s40261-013-0103-z","volume":"33","author":"R Abbas","year":"2013","unstructured":"Abbas R, Leister C, Sonnichsen D. A Clinical study to examine the potential effect of lansoprazole on the pharmacokinetics of bosutinib when administered concomitantly to healthy subjects. Clin Drug Investig. 2013;33:589\u201395.","journal-title":"Clin Drug Investig"},{"key":"391_CR43","unstructured":"Abbas-Borhan R, Chaudhary I, Hug BA, Leister C, Burns J, Vashishtha S, et\u00a0al. Mass balance, metabolic disposition, metabolite characterization, and pharmacokinetics of oral 14C-labeled bosutinib in healthy subjects [poster no.\u00a0P350]. In: 9th\u00a0Triennial Meeting, International Society for the Study of Xenobiotics; Istanbul;\u00a04\u20138 Sept 2010."},{"issue":"4","key":"391_CR44","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1158\/1078-0432.CCR-11-2378","volume":"18","author":"A Daud","year":"2012","unstructured":"Daud A, Krishnamurthi S, Saleh M, Gitlitz BJ, Borad MJ, Gold PJ, et al. Phase\u00a01 study of bosutinib, a SRC\/ABL tyrosine kinase inhibitor, administered to patients with advanced solid tumors. Clin Cancer Res. 2012;18(4):1092\u2013100.","journal-title":"Clin Cancer Res"},{"key":"391_CR45","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/clpt.2008.141","volume":"84","author":"SU Yasuda","year":"2008","unstructured":"Yasuda SU, Zhang L, Huang SM. The role of ethnicity in variability in response to drugs: focus on clinical pharmacology studies. Clin Pharmacol Ther. 2008;84:417\u201323.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"391_CR46","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1007\/s12185-014-1722-8","volume":"101","author":"C Nakaseko","year":"2015","unstructured":"Nakaseko C, Takahashi N, Ishizawa K, Kobayashi Y, Ohashi K, Nakagawa Y, et al. A phase\u00a01\/2 study of bosutinib in Japanese adults with Philadelphia chromosome\u2013positive chronic myeloid leukemia. Int J Hematol. 2015;101(2):154\u201364.","journal-title":"Int J Hematol"},{"issue":"21","key":"391_CR47","doi-asserted-by":"crossref","first-page":"4440","DOI":"10.1182\/blood.V120.21.4440.4440","volume":"120","author":"PH Hsyu","year":"2012","unstructured":"Hsyu PH, Gogat K, Duvillie L, Kelly V, Besson N. Pharmacokinetics and tolerability of bosutinib in Asian versus non-Asian patients with Philadelphia chromosome\u2013positive leukemia. Blood. 2012;120(21):4440.","journal-title":"Blood"},{"key":"391_CR48","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s00280-012-1987-7","volume":"71","author":"R Abbas","year":"2013","unstructured":"Abbas R, Chalon S, Leister C, EI Gaaloul M, Sonnichsen D. Evaluation of the pharmacokinetics and safety of bosutinib in patients with chronic hepatic impairment and matched healthy subjects. Cancer Chemother Pharmacol. 2013;71:123\u201332.","journal-title":"Cancer Chemother Pharmacol"},{"key":"391_CR49","unstructured":"PRODUCT MONOGRAPH - BOSULIF\u2122, Kirkland, Quebec: Pfizer Canada Inc; 2014. http:\/\/www.pfizer.ca\/sites\/g\/files\/g10017036\/f\/201410\/BOSULIF.pdf . Accessed 31 Mar 2016."},{"key":"391_CR50","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1021\/jm0102250","volume":"44","author":"DH Boschelli","year":"2001","unstructured":"Boschelli DH, Ye F, Wang YD, Dutia M, Johnson SL, Wu B, et al. Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of SRC kinase activity. J Med Chem. 2001;44:3965\u201377.","journal-title":"J Med Chem"},{"issue":"10","key":"391_CR51","doi-asserted-by":"crossref","first-page":"922","DOI":"10.2174\/156802608784911653","volume":"8","author":"DH Boschelli","year":"2008","unstructured":"Boschelli DH. Exploitation of the 3-quinolinecarbonitrile template for SRC tyrosine kinase inhibitors. Curr Top Med Chem. 2008;8(10):922\u201334.","journal-title":"Curr Top Med Chem"},{"key":"391_CR52","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1016\/j.ejca.2010.02.032","volume":"46","author":"F Boschelli","year":"2010","unstructured":"Boschelli F, Arndt K, Gambacorti-Passerini C. Bosutinib: a review of preclinical studies in chronic myelogenousleukaemia. Eur J Cancer. 2010;46:1781\u20139.","journal-title":"Eur J Cancer"},{"issue":"3 Suppl 8","key":"391_CR53","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0037-1963(01)90111-8","volume":"38","author":"O Witte","year":"2001","unstructured":"Witte O. The role of BCR-ABL in chronic myeloid leukemia and stem cell biology. Semin Hematol. 2001;38(3 Suppl 8):3\u20138.","journal-title":"Semin Hematol"},{"key":"391_CR54","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/leu.2008.334","volume":"23","author":"LL Remsing","year":"2009","unstructured":"Remsing LL, Rix U, Colinge J, Hantschel O, Bennett KL, Stranzl T, et al. Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells. Leukemia. 2009;23:477\u201385.","journal-title":"Leukemia"},{"key":"391_CR55","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1038\/nbt1328","volume":"25","author":"M Bantscheff","year":"2007","unstructured":"Bantscheff M, Eberhard D, Abraham Y, Hantschel O, Bennett KL, Stranzl T, et al. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat Biotechnol. 2007;25:1035\u201344.","journal-title":"Nat Biotechnol"},{"key":"391_CR56","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1182\/blood-2007-05-092056","volume":"111","author":"H Konig","year":"2008","unstructured":"Konig H, Holyoake TL, Bhatia R. Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual SRC\/ABL kinase inhibitor SKI-606. Blood. 2008;111:2329\u201338.","journal-title":"Blood"},{"key":"391_CR57","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1146\/annurev.cellbio.13.1.513","volume":"13","author":"SM Thomas","year":"1997","unstructured":"Thomas SM, Brugge JS. Cellular functions regulated by SRC family kinases. Annu Rev Cell Dev Biol. 1997;13:513\u2013609.","journal-title":"Annu Rev Cell Dev Biol."},{"issue":"8","key":"391_CR58","first-page":"28","volume":"1","author":"DH Boschelli","year":"2005","unstructured":"Boschelli DH, Boschelli F, Wu B, Ye F, Wang Y, Golas JM, et al. SKI-606 and beyond. Hematol Rep. 2005;1(8):28\u201331.","journal-title":"Hematol Rep."},{"key":"391_CR59","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s00280-012-1998-4","volume":"71","author":"PH Hsyu","year":"2013","unstructured":"Hsyu PH, Mould DR, Upton RN, Amantea M. Pharmacokinetic\u2013pharmacodynamic relationship of bosutinib in patients with chronic phase chronic myeloid leukemia. Cancer Chemother Pharmacol. 2013;71:209\u201318.","journal-title":"Cancer Chemother Pharmacol"},{"key":"391_CR60","doi-asserted-by":"crossref","first-page":"E304","DOI":"10.1002\/ijc.27348","volume":"131","author":"R Abbas","year":"2012","unstructured":"Abbas R, Hug BA, Leister C, Sonnichsen D. A randomized, crossover, placebo- and moxifloxacin-controlled study to evaluate the effects of bosutinib (SKI-606), a dual SRC\/ABL tyrosine kinase inhibitor, on cardiac repolarization in healthy adult subjects. Int J Cancer. 2012;131:E304\u201311.","journal-title":"Int J Cancer"},{"issue":"9","key":"391_CR61","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1016\/j.clinthera.2012.07.006","volume":"34","author":"R Abbas","year":"2012","unstructured":"Abbas R, Leister C, El Gaaloul M, Chalon S, Sonnichsen D. Ascending single-dose study of the safety profile, tolerability, and pharmacokinetics of bosutinib coadministered with ketoconazole to healthy adult subjects. Clin Ther. 2012;34(9):2011\u20139.","journal-title":"Clin Ther"},{"issue":"9","key":"391_CR62","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.3109\/10428194.2013.876631","volume":"55","author":"AV Chintakuntlawar","year":"2014","unstructured":"Chintakuntlawar AV, Finnes HD, Tefferi A, Pardanani A. Drug drug interaction between bosutinib and warfarin. Leuk Lymphoma. 2014;55(9):2213\u20134.","journal-title":"Leuk Lymphoma."},{"key":"391_CR63","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1172\/JCI116064","volume":"90","author":"JC Kolars","year":"1992","unstructured":"Kolars JC, Schmiedlin-Ren P, Schuetz JD, Fang C, Watkins PB. Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J Clin Invest. 1992;90:1871\u20138.","journal-title":"J Clin Invest."},{"key":"391_CR64","unstructured":"Hsyu PH, Matschke K, Soriano-Pignataro D. An open-label, randomized, 2-period crossover study to evaluate the effect of a single oral dose of aprepitant, a moderate CYP3A inhibitor on bosutinib administered orally to healthy subjects [poster no. W5231]. In: 2015 Annual Meeting, American Association of Pharmaceutical Scientists; Orlando;\u00a025\u201329 Oct 2015."},{"key":"391_CR65","unstructured":"Hsyu PH, Matschke K, Soriano-Pignataro D. An open-label, randomized, 2-period crossover study to evaluate the effect of a single oral dose of bosutinib on the pharmacokinetics of dabigatran etexilate mesylate administered orally to healthy subjects [poster no.\u00a0W5230]. In: 2015 Annual Meeting, American Association of Pharmaceutical Scientists; Orlando;\u00a025\u201329 Oct 2015."}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-016-0391-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40262-016-0391-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-016-0391-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-016-0391-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,18]],"date-time":"2020-09-18T22:11:49Z","timestamp":1600467109000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40262-016-0391-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,25]]},"references-count":65,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["391"],"URL":"https:\/\/doi.org\/10.1007\/s40262-016-0391-6","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,25]]}}}